Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 22;25(1):917.
doi: 10.1186/s12885-025-14342-2.

Retrospective analysis of pembrolizumab-related adverse reactions and death outcomes based on the FAERS database

Huilin Xu  1 , Ying Huang  2 , Nan Zhao  3 , Han Hu  2 , Dedong Cao  4
Affiliations

Retrospective analysis of pembrolizumab-related adverse reactions and death outcomes based on the FAERS database

Huilin Xu et al. BMC Cancer. .

Abstract

Objective: This study aimed to analyze the characteristics of adverse reactions in cancer patients treated with Pembrolizumab based on the U.S. Food and Drug Administration's Adverse Event Reporting System (FAERS) database, and to assess the characteristics and risk factors of fatality reports.

Methods: The study data was sourced from the FAERS database, collecting adverse event reports related to Pembrolizumab from 2013 to June 2024. The main analysis variables included gender, age, cancer type, country, reporter type, and adverse reaction outcomes. Descriptive statistics, univariate analysis, and multivariate Logistic regression models were used to assess the relationship between each variable and fatal outcome.

Results: A total of 46,883 adverse reactions were collected, including 5,483 reports with fatal outcomes. The number of events has been increasing since 2013, especially peaking in 2022 and 2023. The United States and Japan had the highest number of adverse reaction reports. The number of serious events reported increased significantly with age, especially in the 51-65 and 66-80 age groups. The age of patients who died was concentrated in the elderly group (≥ 65 years old), and the median treatment duration time of pembrolizumab was 17 days. Analysis showed that gender (OR = 0.75; 95%CI: 0.71-0.80, p < 0.01), age (OR = 0.89; 95%CI: 0.84-0.96, p < 0.01), and ingredients count (OR = 1.92; 95%CI: 1.84-2.01, p < 0.01) were significantly associated with the treatment duration of pembrolizumab.

Conclusion: The serious adverse reactions in cancer patients treated with Pembrolizumab are closely related to patient individual characteristics and cancer types. It is necessary to strengthen the monitoring of high-risk groups such as the elderly in clinical treatment to reduce the risk of fatal outcomes.

Keywords: Adverse reactions; FAERS; Immunotherapy; Pembrolizumab; Prognostic factors.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: This study was conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. As this research was based on publicly available data, no ethical approval was required. Informed consent was not applicable as the study was retrospective design. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of identifying eligible reports
Fig. 2
Fig. 2
Overall trends of pembrolizumab related adverse events in recent years. A number of adverse events by years (2013–2023 and 2024 Q1-Q2); B number of died cases by years (2013–2023 and 2024 Q1-Q2)
Fig. 3
Fig. 3
General features of adverse events in patients treated with pembrolizumab. A number of cases in different reaction groups by sex; B number of various outcomes in different years (2013–2023 and 2024 Q1-Q2); C number of cases in different reaction groups by age; D number of died cases in different reaction groups by age
Fig. 4
Fig. 4
Treatment time of pembrolizumab in died patients. A Treatment time of pembrolizumab by drug number; B Treatment time of pembrolizumab by sex; C Treatment time of pembrolizumab by median age; D Treatment time of pembrolizumab by reporter
See this image and copyright information in PMC

References

    1. Doi T, Piha-Paul SA, Jalal SI, Saraf S, Lunceford J, Koshiji M, Bennouna JJJCO. Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma. 2018, 36(1):61–7. - PubMed
    1. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu W-J, Gangadhar TCJTL. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. 2014, 384(9948):1109–17. - PubMed
    1. Tan S, Zhang CW. Gao GFJSt, therapy t: seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint Blockade tumor immunotherapy. 2016, 1(1):1–4. - PMC - PubMed
    1. Patel SP, Othus M, Chen Y, Wright GP Jr, Yost KJ, Hyngstrom JR, Hu-Lieskovan S, Lao CD, Fecher LA. Truong T-GJNEJoM: Neoadjuvant–adjuvant or adjuvant-only pembrolizumab in advanced melanoma. 2023, 388(9):813–23. - PMC - PubMed
    1. Chen R, Manochakian R, James L, Azzouqa A-G, Shi H, Zhang Y, Zhao Y, Zhou K. Lou YJJoh, oncology: emerging therapeutic agents for advanced non-small cell lung cancer. 2020, 13:1–23. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources